Navigation Links
PAREXEL And Korea Drug Development Fund Announce Alliance To Accelerate Global Drug Development And Commercialization
Date:7/19/2012

for its selected investments. These services are tailored to meet the needs of Korean national companies and will span the entire drug development continuum. 

The alliance with KDDF follows PAREXEL's 2012 collaborative research agreement with ASAN Medical Center (AMC), based in Seoul, Korea. PAREXEL is one of Asia's leading providers of biopharmaceutical services and has had a presence in the Asia/Pacific region for over 16 years. PAREXEL has more than 2,800 employees and 21 offices throughout important industry centers in the region, including locations in Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, the Philippines, Singapore, South Korea, Taiwan, and Thailand. PAREXEL experts support biopharmaceutical companies in accessing diverse patient populations, navigating regulatory issues, identifying investigators, and ensuring data quality throughout the Asia/Pacific region.

About PAREXEL International PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement.  Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process.  Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 50 countries around the world, and has approximately 11,920 employees. F
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2012 Earnings Release and Conference Call
2. PAREXEL International To Present At NASDAQ OMX Investor Conference
3. PAREXEL International Issues Earnings Guidance In Conjunction With Investor Day
4. PAREXEL Chairman And CEO To Ring The Bell At The NASDAQ Stock Market Opening
5. Parexel Invites Public To Listen To Live Webcast Of Its Investor Day May 31, 2012
6. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
7. PAREXEL Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award
8. Misonix And Soelim Create New Distribution Alliance For South Korea
9. Marken Opens Branch Office In Seoul, South Korea
10. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
11. HIV Immunity Study Could Pave Way for Vaccine Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014  Actavis plc (NYSE: ... received a complete response letter from the U.S. ... Drug Application (NDA) for the fixed-dose combination (FDC) ... hypertension.   Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... the receipt of a complete response letter, Actavis ...
(Date:12/24/2014)... -- The International Trade Commission (ITC) issued its final decision in ... a notice issued on December 23, the ITC ruled in ... humidifier was invalid. BMC President, James Xu ... excited with the ITC,s decision in this case. This victory ... the very beginning on the key patents in the case. ...
(Date:12/24/2014)... -- PuraMed BioScience®, Inc., (OTC Pink: PMBS), a researcher, ... products, announced it received the initial funding to begin ... relief product, for planned distribution to 1,000 medical and ... Washington State , and ... Advanced headache relief gel formulation completed, PuraMed BioScience has ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3
... with Turner ... ... Norditropin(R) (somatropin [rDNA origin] injection) received,approval from the U.S. Food and ... with Turner syndrome. Turner,syndrome is a rare chromosomal condition caused by ...
... NeurogesX, Inc.,(Nasdaq: NGSX ) announced today ... second Phase 3 clinical trial of its lead ... sensory polyneuropathy,(HIV-DSP). NGX-4010 is a dermal patch designed ... trials demonstrated that a,single, 30- or 60-minute treatment ...
Cached Medicine Technology:Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome 2Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome 3Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome 4Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome 5Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome 6NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy 2NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy 3NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy 4
(Date:12/25/2014)... (PRWEB) December 26, 2014 “Every three months ... market changes. A-line sweetheart evening dress will be one of ... sales manager of Yunx.co.uk says. Today, the company releases 26 ... discounts, up to 80% off. , “We are trying ... unique style with our latest designs. Along with affordable prices, ...
(Date:12/25/2014)... Recently, BellasDress has launched its Christmas ... BellasDress has chosen their best-selling lace wedding dresses, vintage ... holiday season. , Now, BellasDress.com features popular women’s ... at discount prices. The business hopes everyone can have ... , “All our elegant products are made with ...
(Date:12/25/2014)... LunaDress.co.uk has updated its blog to provide professional shopping tips on ... models at LunaDress.co.uk come with big discounts, up to 80 percent ... turn out to be a most exciting memory and can show ... surprise to a wedding. On the updated fashion blog, ladies can ... a big day . , Going out with friends to a ...
(Date:12/25/2014)... 24, 2014 (HealthDay News) -- Among early stage breast ... than half of one percent will eventually develop leukemia ... reveals. The finding comes from a review of ... and 2007, and it suggests that the risk for ... experts had previously thought. "The frequency of bone ...
(Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch as ... coolest mobile applications on the iOS, Android, and Windows markets. ... conducted the app review and shared with viewers how this ... The old saying goes, “A picture says a thousand words.” ... describe a single image, because each picture holds a unique ...
Breaking Medicine News(10 mins):Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2
... AMERIGROUP,Corporation (NYSE: AGP ) today announced that ... Conference on November 13 in Phoenix,Arizona., A live ... at 4:00 p.m. Eastern Time, can be accessed on ... A replay will,be available for 30 days, and can ...
... LOS ANGELES, Oct. 30 Members of SEIU ... collective bargaining,agreements that will make improvements for hundreds ... several California nursing homes., In all, seven ... wage increases of $1.50/hr over three years, employer ...
... age of disease onset and nerve cell death , , ... genes may be linked to the most common form ... team, from Massachusetts General Hospital-MassGeneral Institute for Neurological Disease ... families with a history of the devastating neurological disorder. ...
... Medical, Inc.,(Nasdaq: ATSI ), manufacturer and marketer ... it has received U.S. Food,and Drug Administration (FDA) ... http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO ), This is the Company,s ... market. Based on the precept that ,Form Follows ...
... WellPoint,s commercial marketing,team was awarded a silver ... its innovative campaign, "Ecosphere -- Simple is more ... Awards competition is the only international,award that honors ... response results., WellPoint,s campaign, conducted through its ...
... AGA Medical Holdings ("AGA,Medical", "AGA") announced today its ... Court in the Netherlands related to a proceeding,brought ... lawsuit,sought invalidity and/or non-infringement declarations related to AGA,Medical,s ... its European patents,for intravascular occlusion devices and the ...
Cached Medicine News:Health News:Scientists Spot 4 New Alzheimer's Genes 2Health News:ATS Medical Announces FDA Approval of the ATS 3f Aortic Bioprosthesis 2Health News:ATS Medical Announces FDA Approval of the ATS 3f Aortic Bioprosthesis 3Health News:ATS Medical Announces FDA Approval of the ATS 3f Aortic Bioprosthesis 4Health News:WellPoint Awarded Prestigious International Marketing Award 2Health News:AGA Medical to Appeal Ruling by Dutch Court in Lawsuit With Occlutech GmbH 2
... Blot is an FDA approved confirmatory test ... fluid sample. Repeatedly reactive results of initial ... HIV-1 Microelisa System can be confirmed with ... the same OraSure sample. The OraSure HIV-1 ...
Prognosis / Patient Management. HIV-1 Viral Load Assay. NucliSens HIV-1 QT covers the entire dynamic range of viral load testing from a single patient sample, without reflex testing or thermalcycli...
... genome of the Human Immunodeficiency Virus (HIV-1) ... in response to anti-viral drug treatment. Some ... render the virus resistant to the action ... the treatment.,The detection of mutations in HIV-1 ...
EIA for Donor Screening. Synthetic peptide Enzyme Immunoassay (EIA) for the detection of antibodies to Human Immunodeficiency Virus Types 1 and/or 2,(HIV-1 and HIV-2) in human serum, plasma or ca...
Medicine Products: